Frontiers of lung cancer screening

Joint session
Chairs: R. Gosens (Groningen, Netherlands), O. Burghuber (Wien, Austria)
Aims: Please note that this session is not CME accredited.

To present cost-effectiveness of lung cancer screening with CT-scan; to discuss the role of artificial intelligence in lung cancer screening; to assess risks and advantages of radiation therapy and the possible effects (radiation injury, second primary cancer) This session is made possible thanks to the financial support of the following companies: AstraZeneca, F. Hoffmann - La Roche & Siemens Healthineers

Introduction J. van Meerbeeck (Edegem (Antwerp), Belgium)
Cost-effectiveness of lung cancer screening with CT-scan H. De Koning (Rotterdam, Netherlands)
The role of artificial intelligence in lung cancer screening C. Jacobs (Nijmegen, Netherlands)
Radiation injury and second primary cancer: risk or asset? C. Franck (Edegem, Belgium)